Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com -- Vir Biotechnology Inc (NASDAQ:VIR) stock rose 4.3% Thursday after the company announced it has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors.
The trial will assess VIR-5500, a dual-masked T-cell engager targeting prostate-specific membrane antigen (PSMA), in patients with first-line pre-taxane metastatic castration-resistant prostate cancer. According to the company, VIR-5500 is the only dual-masked PSMA-targeting T-cell engager currently in clinical trials.
The Phase 1 trial is designed to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5500 in combination with androgen receptor pathway inhibitors in participants with metastatic prostate cancer. The company noted that VIR-5500 has already shown promising early anti-tumor activity and a favorable safety profile as a monotherapy in heavily pre-treated patients.
"Opening Part 3 of the Phase 1 trial brings the potential benefits of the universal PRO-XTEN approach to patients earlier in their cancer journey, when treatment intervention may have the greatest impact on their long-term outcomes," said Marianne De Backer, Chief Executive Officer of Vir Biotechnology.
The company highlighted that VIR-5500 incorporates its PRO-XTEN masking technology, which is designed to selectively activate in the tumor microenvironment, potentially reducing toxicity to healthy cells.
Prostate cancer remains the most diagnosed cancer in men, with metastatic forms of the disease progressing rapidly and having limited treatment options despite recent advances.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.